Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
about
Contemporary Management of Prostate CancerThe course of metastatic prostate cancer under treatment.Current and emerging therapies for bone metastatic castration-resistant prostate cancer.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
P2860
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@ast
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@en
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@nl
type
label
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@ast
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@en
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@nl
prefLabel
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@ast
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@en
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@nl
P2860
P356
P1476
Beyond abiraterone: new hormon ...... ion-resistant prostate cancer.
@en
P2093
Álvaro Pinto
P2860
P304
P356
10.4161/CBT.26724
P577
2013-11-01T00:00:00Z